Ovid Therapeutics Inc. expected to post a loss of 11 cents a share - Earnings Preview

Ovid Therapeutics

07/08/2026 17:20

Ovid Therapeutics Inc. OVID.OQ OVID.O is expected to  show a fall in quarterly revenue when it reports  results on August 11 (estimated) for the period ending June 30 2026

​LSEG's mean analyst estimate for Ovid Therapeutics Inc. is for a loss of 11 cents per share. 
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 10 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."  
The mean earnings estimate of analysts was unchanged in the last three months. ​
Wall Street's median 12-month price target for Ovid Therapeutics Inc. is $5.00, about 88.7% above its last closing price of $2.65
Previous quarterly performance (using preferred earnings measure in US dollars). ​
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE 
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2026
-0.12
-0.12
-0.12
Met
0.2
Dec. 31 2026
-0.10
-0.12
0.06
Beat
150.4
Sep. 30 2025
-0.15
-0.15
-0.17
Missed
-13.4​
Jun. 30 2025
-0.16
-0.16
-0.06
Beat
62.9
​​Mar. 31 2025
-0.14
-0.14
-0.14
Met
-2.4
Dec. 31 2024
-0.17
-0.17
-0.13
Beat
21.7​
Sep. 30 2024
-0.19
-0.20
-0.20
Met
1.9
Jun. 30 2024
-0.20
-0.22
0.12
Beat
154.1
This summary was machine generated August 7 at 16:20 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)